OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the Company has achieved its 2015 corporate goals for the OvaPrimeSM and OvaTureSM fertility treatments.

  • OvaPrime Treatment Preceptorship Program
    OvaScience commenced a non-commercial preceptorship program with the OvaPrime treatment at an in vitrofertilization (IVF) clinic outside of the United States to gain insight into the clinical efficacy and feasibility of the treatment. The Company expects that physicians using the treatment will report patient experiences by the end of 2016, as clinically meaningful information becomes available.

    The OvaPrime treatment is a potential fertility treatment that could enable a woman to increase her egg reserve. Approximately 25 percent of women who seek IVF treatment do not make enough or any eggs and therefore are not candidates for IVF. The OvaPrime treatment is designed to transfer a patient’s egg precursor (EggPCSM) cells, immature egg cells found inside the protective ovarian lining, to the patient’s ovaries, where they may mature into fertilizable eggs during a standard IVF process.

  • OvaTure Treatment Clinical Development Strategy
    OvaScience has also defined the process for maturing EggPC cells that is required for OvaTure development. Maturation of EggPC cells to eggs in vitro, or outside the body, would eliminate the need for the hormone hyperstimulation currently required for IVF. The Company’s progress in developing the OvaTure treatment has provided important insights that enabled the treatment to move into clinical translation.

    The OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing her EggPC cells into eggs outside the body. It may be an option for women with compromised eggs, who are unable to make eggs or who may be unwilling or unable to undergo hormone hyperstimulation, such as women diagnosed with cancer.

  • AUGMENT Treatment
    Since its introduction in select international IVF clinics, the AUGMENT treatment has resulted in positive patient experiences for poor prognosis patients, including the births of 22 babies. The clinical experience with the treatment was published in three journals, including a recent review of EggPC cell mitochondria.i, ii, iii

    The AUGMENT treatment is designed to improve egg health by supplementing a woman’s mature eggs with EggPC cell mitochondria during IVF. The treatment is not available in the U.S.

  • Investor Day
    The Company has rescheduled its Investor Day to the first half of 2016 and will present at the Oppenheimer 26th Annual Healthcare Conference in December 2015 and at the J.P. Morgan Healthcare Conference inJanuary 2016.

“The promising development of our OvaPrime and OvaTure fertility treatment programs represent new options for women who would like to have their own children but are unable to undergo IVF due to a lack of eggs, as well as those who do not want to endure hormone treatments,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer ofOvaScience. “In addition, based on our learnings in 2015, we continue to adapt our commercial operations and infrastructure focused on driving the future commercial success of our AUGMENT treatment. We look forward to providing further details in 2016.” (Original Source)

Shares of OvaScience closed today at $9.25, down $0.85 or -8.42%. OVAS has a 1-year high of $55.69 and a 1-year low of $7.90. The stock’s 50-day moving average is $11.91 and its 200-day moving average is $21.50.

On the ratings front, OvaScience has been the subject of a number of recent research reports. In a report issued on November 9, Leerink Swann analyst Paul Matteis downgraded OVAS to Hold, with a price target of $14, which represents a potential upside of 51.4% from where the stock is currently trading. Separately, on October 21, Oppenheimer’s Rohit Vanjani reiterated a Buy rating on the stock and has a price target of $16.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Paul Matteis and Rohit Vanjani have a total average return of -19.4% and 20.9% respectively. Matteis has a success rate of 30.4% and is ranked #3513 out of 3645 analysts, while Vanjani has a success rate of 63.0% and is ranked #81.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.